.jpg "Vir Biotechnology (NASDAQ: VIR)")
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report) and Pfizer (PFE – Research Report).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vir Biotechnology (VIR)
In a report issued on December 20, Joel Beatty from Robert W. Baird downgraded Vir Biotechnology to Sell, with a price target of $36.00. The company’s shares closed last Tuesday at $39.38, close to its 52-week low of $25.31.
According to TipRanks.com, Beatty is a 4-star analyst with an average return of
Vir Biotechnology has an analyst consensus of Hold, with a price target consensus of $105.80.
See the top stocks recommended by analysts >>
Pfizer (PFE)
In a report issued on December 22, Geoff Porges from Leerink Partners maintained a Hold rating on Pfizer, with a price target of $56.00. The company’s shares closed last Tuesday at $58.01, close to its 52-week high of $61.43.
According to TipRanks.com, Porges is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $56.12 average price target, which is a -5.0% downside from current levels. In a report issued on December 17, Goldman Sachs also initiated coverage with a Hold rating on the stock with a $51.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIR: